The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .
The incidence of cough: a comparison of lisinopril, placebo and telmisartan, a novel angiotensin II antagonist. Telmisartan Cough Study Group.
Dry cough is a troublesome side-effect associated with certain antihypertensive agents that act by modulating aspects of the renin-angiotensin-aldosterone system . The incidence of dry cough associated with two of these therapies , the novel All receptor antagonist telmisartan and the ACE inhibitor lisinopril , was assessed in a multicentre , r and omised , parallel-group , double-blind , placebo-controlled , 8-week study of 88 patients with mild to moderate hypertension who previously demonstrated ACE inhibitor-related cough . Patients received either telmisartan 80 mg , lisinopril 20 mg , or placebo once daily . Cough incidence , measured at each visit by a self-administered symptom assessment question naire , was significantly higher with lisinopril ( 60 % ) than with telmisartan ( 15.6 % ) or placebo ( 9.7 % ) . A visual analogue scale demonstrated a similar trend for cough frequency . Thus the incidence of cough with telmisartan 80 mg is significantly less than that seen with lisinopril 20 mg and is comparable to placebo
The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .